GSK Plc plans annual savings of £1.9 billion by 2029 as its new chief executive seeks to boost research and development spending, according to Bloomberg.
The drugmaker said the cost cuts will help fund a bigger pipeline investment as it looks to replace revenue from an HIV medicine facing patent expiry.
GSK Targets £1.9 Billion in Annual Savings by 2029
2026-07-28 11:22:43
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Next article：
伊朗外长与日本外相讨论海峡安全合作
